Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02324699 · ClinicalTrials.gov registry record · Phase 4
Corticosteroids With Vedolizumab in Crohn's Disease
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT02324699 is a Phase 4 study that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 1 participants.
The verdict
NCT02324699, a Phase 4 study, was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
Use of co-induction with corticosteroid therapies may accelerate the remission rate when used with vedolizumab. Further, this may lead to higher rates of response and remission at week 10 than would be seen with vedolizumab monotherapy.
Interventions
- DRUG Placebo
- DRUG Prednisone
- DRUG Vedolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-04 |
| Est. Completion | 2018-02-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02324699
The ClinicalTrials.gov registry entry for NCT02324699 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02324699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02324699 about?
NCT02324699 is a clinical study titled "Corticosteroids With Vedolizumab in Crohn's Disease". Use of co-induction with corticosteroid therapies may accelerate the remission rate when used with vedolizumab. Further, this may lead to higher rates of response and remission at week 10 than would be seen with vedolizumab monotherapy.
What is the current status of trial NCT02324699?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2016-04. Estimated completion is 2018-02-08.
What interventions are being tested in trial NCT02324699?
The interventions under investigation include: Placebo (DRUG), Prednisone (DRUG), Vedolizumab (DRUG).
Who is sponsoring clinical trial NCT02324699?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.